NGL FINECHEM
|
|
BOM : 524774     NSE : NGLFINE     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jun 07,2023 |
Price(EOD): βΉ 1,518.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 941.69 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NGL FINECHEM | 1.7% | 2.2% | -20.6% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 5.9% | 17.9% |
DIVIS LABORATORIES | 0.5% | 4.8% | 0.3% |
CIPLA | -0.4% | 2.3% | -1.5% |
DR REDDYS LABORATORIES | 2.6% | -5.3% | 7% |
TORRENT PHARMACEUTICALS | 1.5% | 9.3% | 27.1% |
ABBOTT INDIA | 1.3% | -0.2% | 18.8% |
ZYDUS LIFESCIENCES | 0.3% | -1.9% | 41.3% |
ALKEM LABORATORIES | 0.8% | -5.8% | 9.5% |
FUNDAMENTAL ANALYSIS OF NGL FINECHEM
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NGL FINECHEM
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
44.69
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 21.00 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 4.22
P/B Calculated based on Book Value of Rs 222.55 Cr
[Latest Year - Mar2023 - Consolidated Results ] 3.37
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 278.15 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
323% 603% 592% |
SHARE PRICE MOMENTUM OF NGL FINECHEM
NGL FINECHEM vs SENSEX
DEBT OF NGL FINECHEM
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.15 0.11 0.28 0.18 |
0.15 0.11 0.29 0.18 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NGL FINECHEM
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NGL FINECHEM
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
2.72% 32.2% 33.75% 43.77% |
-12.1% 22.82% 41.37% 35.81% |
QtrlyTrend |
6 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
NGL FINECHEM related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.3% | 7.1% | 18.8% |
S&P BSE HEALTHCARE | 3.2% | 5.1% | 10% |
S&P BSE MIDSMALLCAP | 2.9% | 6.7% | 19.4% |
S&P BSE ALLCAP | 1.6% | 3.9% | 13.8% |
You may also like the below Video Courses
FAQ about NGL FINECHEM
Is NGL FINECHEM good for long term investment?
As on Jun 07,2023, the Fundamentals of NGL FINECHEM look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of NGL FINECHEM . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NGL FINECHEM UnderValued or OverValued?
As on Jun 07,2023, NGL FINECHEM is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NGL FINECHEM ?
As on Jun 07,2023, the Intrinsic Value of NGL FINECHEM is Rs. 219.38 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 358.93
Fair Value [Median EV / Sales Model] : Rs. 216.02
Fair Value [Median Price / Sales Model] : Rs. 219.38
Estimated Median Fair Value of NGL FINECHEM : Rs. 219.38
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is NGL FINECHEM trading at a Premium or Discount?
As on Jun 07,2023, NGL FINECHEM is trading at a Premium of 592% based on the estimates of Median Intrinsic Value!